AD/PD™ Neuro Talks: Early Alzheimer’s in Focus
Exploring new approaches to earlier,
more accessible Alzheimer’s disease diagnosis and care
These series explore emerging advances in Alzheimer’s disease diagnosis and evaluation, with a focus on how blood-based biomarkers could make testing faster, more accurate, and more scalable.
Through expert-led conversations, the series examines the potential of biomarkers across the patient journey from early detection and diagnosis to disease staging, risk stratification, prognosis, and treatment monitoring.
Episodes Line-Up:
- pTau217: Clinical and Economic Benefits to the Healthcare System with Dr. Soeren Mattke
- Blood Tests in Alzheimer’s Disease Diagnosis: Clinical Performance & Implementation with Prof. Craig Ritchie
- pTau217: Clinical Validation by Mayo with Dr. Alicia Algeciras
- pTau217 in Clinical Workflows with Prof. Kristian Steen Frederiksen
🎙️ Episode 1: pTau217 – Clinical and Economic Benefits to the Healthcare System
In the inaugural episode,
Dr. Soeren Mattke, physician and health services researcher at the University of Southern California, explores the growing role of blood-based biomarkers in Alzheimer’s disease.
Subscribe today and be the first to access expert insights when episodes go live!
This is an AD/PD™ initiative in educational collaboration with Roche.